Gandhi Jatin S, Malik Faizan, Amin Mahul B, Argani Pedram, Bahrami Armita
Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, USA.
Department of Pathology, John Hopkins University, Baltimore, MD, USA.
Histol Histopathol. 2020 Feb;35(2):125-136. doi: 10.14670/HH-18-159. Epub 2019 Sep 6.
Microphthalmia (MiT) family translocation renal cell carcinomas (RCCs) are a heterogeneous category of renal tumors which all express MiT transcription factors, typically from chromosomal translocation and rarely from gene amplification. This tumor family has two major subtypes [i.e., Xp11 translocation RCC and t(6;11) RCC] and several related neoplasms (i.e., TFEB amplification RCC and melanotic Xp11 translocation renal cancers). Increased understanding of the clinical, pathological, molecular and prognostic heterogeneity of these tumors, since their official recognition in 2004, provides the opportunity to identify prognostic biomarkers and to understand the reasons for tumor aggression. We will review the literature from the past 15 years and highlight the need for a greater understanding of the molecular mechanisms underpinning heterogeneous tumor behavior.
小眼畸形（MiT）家族易位性肾细胞癌（RCC）是一类异质性肾肿瘤，所有这些肿瘤均表达MiT转录因子，通常源于染色体易位，很少源于基因扩增。该肿瘤家族有两个主要亚型[即Xp11易位性RCC和t(6;11)RCC]以及几种相关肿瘤（即TFEB扩增性RCC和黑色素性Xp11易位性肾癌）。自2004年这些肿瘤被正式确认以来，对其临床、病理、分子及预后异质性的认识不断增加，这为识别预后生物标志物及理解肿瘤侵袭的原因提供了机会。我们将回顾过去15年的文献，并强调更深入了解支撑异质性肿瘤行为的分子机制的必要性。
